AA
ONCE

Ancora Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Ancora Advisors’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,000
Closed -$205K – 673
2019
Q2 		$205K Buy
+2,000
New +$216K 0.01% 546

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Ancora Advisors's ONCE Position: Q3 2019 in Review

Ancora Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2019, closing a stake of 2,000 shares — an estimated $205K sold.

Ancora Advisors first reported a position in ONCE in Q2 2019 and held it in 1 quarter. The position peaked at $205K in Q2 2019. 184 funds tracked by Wall St. Rank hold ONCE as of Q3 2019.

  • Ancora Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Ancora Advisors sold 2,000 Spark Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $205K.
  • Ancora Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Ancora Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $205K in Q2 2019.
  • 184 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Ancora Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.